Get access
Journal of Cellular Biochemistry

Non-coding RNAs as theranostics in human cancers

Authors

  • Roxana S. Redis,

    1. Department of Molecular Science, University of Medicine and Pharmacy I. Hatieganu, Cluj-Napoca, Romania
    2. Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas 77054
    Search for more papers by this author
  • Ioana Berindan-Neagoe,

    1. Department of Oncology, University of Medicine and Pharmacy I. Hatieganu, Cluj-Napoca, Romania
    2. Oncological Institute I. Chiricuta, Cluj-Napoca, Romania
    Search for more papers by this author
  • Victor I. Pop,

    1. Department of Molecular Science, University of Medicine and Pharmacy I. Hatieganu, Cluj-Napoca, Romania
    Search for more papers by this author
  • George A. Calin

    Corresponding author
    1. Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas 77054
    • University of Texas, MD Anderson Cancer Center, 1881 East Road Unit 1850, Houston, TX 77054.
    Search for more papers by this author

Abstract

Theranostics was coined originally as a term used to describe a system that combines diagnosis and therapy, aiming to provide the tools for personalized medicine. This review reasserts the grounds for regarding non-coding RNAs (ncRNA) as theranostics in human cancers. The microRNAs (miRNAs) are the most well studied ncRNAs in recent years; their pivotal role in orchestrating tumor initiation and progression has been confirmed in all types of cancers. Hence, these small ncRNAs have emerged as attractive therapeutic targets and diagnostic tool. Various approaches to use their therapeutic potential have been taken, here we summarize the most important ones. In the near future, the focus of theranostics will be shifted towards longer and mechanistically more versatile ncRNAs, and we included some recent advances supporting this view. J. Cell. Biochem. 113: 1451–1459, 2012. © 2011 Wiley Periodicals, Inc.

Get access to the full text of this article

Ancillary